Novo Nordisk and Eli Lilly are concentrating on tablet computer variations of GLP-1 medicines. Zealand Pharma is taking a various strategy with amylin.
发布者:BY MARKETWIRE,转转请注明出处:https://robotalks.cn/zealand-pharma-explores-opportunities-in-weight-loss-pill-market/